CASC
SUPN icon

Coppell Advisory Solutions Corp’s Supernus Pharmaceuticals SUPN Stock Holding History

Coppell Advisory Solutions Corp’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-9
Closed -$321 – 958
2022
Q4 		$321 Buy
+9
New +$313 ﹤0.01% 1072

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Coppell Advisory Solutions Corp's SUPN Position: Q1 2023 in Review

Coppell Advisory Solutions Corp sold out of Supernus Pharmaceuticals (SUPN) in Q1 2023, closing a stake of 9 shares — an estimated $321 sold.

Coppell Advisory Solutions Corp first reported a position in SUPN in Q4 2022 and held it in 1 quarter. The position peaked at $321 in Q4 2022. 258 funds tracked by Wall St. Rank hold SUPN as of Q1 2023.

  • Coppell Advisory Solutions Corp reported no remaining Supernus Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Coppell Advisory Solutions Corp sold 9 Supernus Pharmaceuticals shares in Q1 2023, an estimated $321.
  • Coppell Advisory Solutions Corp first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Coppell Advisory Solutions Corp's Supernus Pharmaceuticals position peaked at $321 in Q4 2022.
  • 258 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2023.

Based on Coppell Advisory Solutions Corp's 13F filing for Q1 2023, filed 10 May 2023.